Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial

Abstract Background We report results from a phase II randomised placebo-controlled trial assessing zibotentan, a highly selective endothelin receptor antagonist (ERA), in chronic kidney disease (CKD) secondary to systemic sclerosis (SSc). Methods This trial included three sub-studies: ZEBRA 1—a ran...

Descrición completa

Detalles Bibliográficos

Principais autores:	Edward P. Stern, Lauren V. Host, Ivy Wanjiku, K. Jane Escott, Peter S. Gilmour, Rachel Ochiel, Robert Unwin, Aine Burns, Voon H. Ong, Helen Cadiou, Aidan G. O’Keeffe, Christopher P. Denton
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMC 2022-06-01
Series:	Arthritis Research & Therapy
Assuntos:	Scleroderma Renal crisis Chronic kidney disease Endothelin Zibotentan
Acceso en liña:	https://doi.org/10.1186/s13075-022-02818-6
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!